XM does not provide services to residents of the United States of America.

Belgium's Syensqo on track for worst day ever after top end forecast cut



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Belgium's Syensqo on track for worst day ever after top end forecast cut</title></head><body>

Annual EBITDA seen in 1.4 bln to 1.475 bln euros range

Q2 EBITDA 378 mln euros vs. 383 mln euros consensus

Updates share move, adds Syensqo and JPM comments

By Alban Kacher and Leo Marchandon

Aug 1 (Reuters) -Syensqo's SYENS.BR shares fell 6% on Thursday after the company lowered the top end of its annual core profit and free cash flow forecast, as it does not expect a broader demand recovery in the final six months of the year.

"The high end (of EBITDA guidance) was factoring in recovery in demand in the second-half of the year. Now with the first six months behind us and landing in line with expectations, we do not see this recovery," the company said in a call.

The Belgian speciality chemicals firm now expects underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) between 1.4 billion euros and 1.475 billion euros ($1.52 billion-$1.60 billion) in 2024, compared with its earlier expectation of 1.4 billion euros to 1.55 billion euros.

It also lowered the free cash flow guidance to 400 million euros-to-450 million euros from 400 million euros and 500 million euros earlier.

"Overall, expectations were low and stock looks very cheap, but somewhat bigger earnings cut than expected for 2H24 might result in underperformance of the shares today," J.P. Morgan said in a note.

Syensqo, which was spun off from Belgian chemicals group Solvay SOLB.BR last year, reiterated its capital expenditure for the year.

The Belgian company expects to return to year-on-year volume growth in the second half with increases across all units, particularly in Novecare.

However, it sees slow recovery in agriculture, industrial, automotive and medical destocking.

Its underlying EBITDA came in at 378 million euros for the second quarter, slightly below analysts' expectations of 383 million euros, according to a company-compiled consensus.

Core profit declined 17% at the materials business, which accounts for 71% of the group's total.

The group's net debt increased by 20% between the end of 2023 and the closing of the second quarter, primarily due to a 167 million euros settlement of claims linked to water pollution in New Jersey.

Chemicals companies have been under pressure for more than a year, forced to reduce inventories on lower demand from industrial clients as energy prices soared.

Syensqo's shares are down 19% this year and on track for their worst day ever, if losses hold.



($1 = 0.9238 euros)



Reporting by Alban Kacher and Leo Marchandon; Editing by Subhranshu Sahu and Mrigank Dhaniwala

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.